METHODS OF USING SELECTIVE DELIVERY MOLECULES
Provided herein, in part, are selective delivery molecules their methods of use in the detection of cancer tissue and surgical excision of said cancer tissue.
1 . (canceled)
2 . A method of surgically excising a plurality of cancerous cells from a subject in need thereof, comprising:
(i) administering to the subject an effective amount of SDM-25,
or a pharmaceutically acceptable salt thereof, at least 12 hours prior to surgery;
(ii) during surgery, contacting a tissue suspected to comprise a plurality of cancerous cells with light having at least one excitation wavelength of the Cy5 dye moiety of SDM-25;
(iii) capturing an image of Cy5 dye moiety fluorescence intensity in the tissue and, optionally, capturing an image of Cy7 dye moiety fluorescence intensity in the tissue;
(iv) detecting a region of the image of Cy5 dye moiety fluorescence intensity in which the image has a Cy5 dye moiety fluorescence intensity above a pre-specified fluorescence intensity threshold value; or
detecting a region of the image of Cy7 dye moiety fluorescence intensity in which the image has a Cy7 dye moiety fluorescence intensity above a pre-specified fluorescence intensity threshold value; or
detecting a region of a fluorescence ratio image of Cy5 dye moiety fluorescence intensity to Cy7 dye moiety fluorescence intensity, in which the ratio image has a Cy5/Cy7 ratio value above a pre-specified threshold value;
thereby identifying the location of the plurality of cancerous cells to be surgically excised from the tissue; and
(v) surgically excising a region of the tissue whose perimeter encompasses the perimeter of the identified location of the plurality of cancerous cells, thereby surgically excising the plurality of cancerous cells from the subject.
3 . (canceled)
4 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 14, 15, 16, 17, 18, 19, 20, or 21 hours prior to surgery.
5 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 14 hours prior to surgery.
6 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 15 hours prior to surgery.
7 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 16 hours prior to surgery.
8 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 17 hours prior to surgery.
9 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is administered to the subject at least 18 hours prior to surgery.
10 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is not administered to the subject more than 21 hours before surgery, preferably, not more than 20.5 hours before surgery, more preferably, not more than 20 hours before surgery.
11 . The method of claim 2 , wherein SDM-25, or pharmaceutically acceptable salt thereof, is intravenously administered to the subject.
12 . The method of claim 2 , wherein the at least one excitation wavelength is about 650 nm.
13 . The method of claim 2 , wherein the plurality of cancerous cells is of a cancer selected from the group consisting of AIDS-related cancers, anal cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, eye cancer, gastric (stomach) cancer, germ cell tumor, head and neck cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, melanoma, Merkel cell carcinoma, neuroendocrine cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, renal cancer, salivary gland cancers, sarcoma, skin cancer, small intestine cancer, squamous cell cancer, testicular cancer, throat cancer, thyroid cancer, urethral cancer, vaginal cancer, and post-transplant lymphoproliferative disorder (PTLD).
14 . The method of claim 2 , wherein the cancerous cell is of a cancer selected from the group consisting of breast cancer, colorectal cancer, melanoma, sarcoma, head and neck carcinoma, ovarian cancer, and prostate cancer.
15 . The method of claim 2 , wherein the cancerous cell is of breast cancer.
16 . The method of claim 2 , wherein the breast cancer is mixed breast cancer, wherein the mixed breast cancer comprises invasive and non-invasive breast cancer.
17 . The method of claim 2 , wherein the breast cancer is an invasive breast cancer.
18 . The method of claim 2 , wherein the breast cancer is a non-invasive breast cancer.
19 . The method of claim 2 , wherein the non-invasive breast cancer is ductal carcinoma in situ.
20 . The method of claim 2 , comprising administering 1 mg to 16 mg of SDM-25, or pharmaceutically acceptable salt thereof, to the subject.
21 . The method of claim 2 , comprising administering 8 mg of SDM-25, or pharmaceutically acceptable salt thereof, to the subject.
22 .- 112 . (canceled)